Given that osimertinib is highly active against T790M-positive tumors [37], a sequential regimen of afatinib followed by osimertinib could be considered in many patients with EGFR mutation-positive NSCLC, which may delay the requirement for chemotherapy. Here, EGFR is linked to non-small cell lung carcinoma.